CoChat
Sign Up
Cited by 139Gene Regulatory Network AnalysisComputational Drug Discovery MethodsBioinformatics and Genomic Networks

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Synergistic and Antagonistic Drug Combinations Depend on Network Topology

Open access
Yin, Ning, Ma, Wenzhe, Pei, Jianfeng, Ouyang, Qi, Tang, Chao, Lai, Luhua·2014·PLoS ONE
DOI 10.1371/journal.pone.0093960PMC PMC3979733
Open this paper in CoChat — free accountOpen PDF

Abstract

Drug combinations may exhibit synergistic or antagonistic effects. Rational design of synergistic drug combinations remains a challenge despite active experimental and computational efforts. Because drugs manifest their action via their targets, the effects of drug combinations should depend on the interaction of their targets in a network manner. We therefore modeled the effects of drug combinations along with their targets interacting in a network, trying to elucidate the relationships between the network topology involving drug targets and drug combination effects. We used three-node enzymatic networks with various topologies and parameters to study two-drug combinations. These networks can be simplifications of more complex networks involving drug targets, or closely connected target networks themselves. We found that the effects of most of the combinations were not sensitive to parameter variation, indicating that drug combinational effects largely depend on network topology. We then identified and analyzed consistent synergistic or antagonistic drug combination motifs. Synergistic motifs encompass a diverse range of patterns, including both serial and parallel combinations, while antagonistic combinations are relatively less common and homogenous, mostly composed of a positive feedback loop and a downstream link. Overall our study indicated that designing novel synergistic drug combinations based on network topology could be promising, and the motifs we identified could be a useful catalog for rational drug combination design in enzymatic systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0093960

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Modeling process to study drug combinations. (A) Illustration of the drug modelling process. An example enzymatic network with corresponding ODEs is shown. Solid links represent inter-node regulatory relationships, broken lines are background regulations. With the addition of drugs to chosen links (shown by crosses), the equations are modified by incorporating drugs as competitive inhibitors. (B) An example isobologram calculated from the combination of links 1 and 2 in (A). Points on isobloles represent dose combinations with the same efficacy. The black isobole (solid line) is concave, suggesting a synergistic interaction between the two links. The tipping point is the point where CI reaches minimum (or maximum for antagonistic cases). Inhibition strength is defined as [I]/Ki, i. e. the concentration of the inhibitor divided by its inhibition constant. The combination indices calculated from inhibition strengths are identical with those calculated with concentrations since KI's cancel. The whole process depicted here was repeated for all (16,038) networks and 100,000 sampled parameter sets.
Figure 1 Modeling process to study drug combinations. (A) Illustration of the drug modelling process. An example enzymatic network with corresponding ODEs is shown. Solid links represent inter-node regulatory relationships, broken lines are background regulations. With the addition of drugs to chosen links (shown by crosses), the equations are modified by incorporating drugs as competitive inhibitors. (B) An example isobologram calculated from the combination of links 1 and 2 in (A). Points on isobloles represent dose combinations with the same efficacy. The black isobole (solid line) is concave, suggesting a synergistic interaction between the two links. The tipping point is the point where CI reaches minimum (or maximum for antagonistic cases). Inhibition strength is defined as [I]/Ki, i. e. the concentration of the inhibitor divided by its inhibition constant. The combination indices calculated from inhibition strengths are identical with those calculated with concentrations since KI's cancel. The whole process depicted here was repeated for all (16,038) networks and 100,000 sampled parameter sets.CC BY · PubMed Central
Figure 2 Distribution of percentage of synergistic cases under various parameter sets for all combinations studied. Consistently synergistic and antagonistic combinations are marked, showing their stark contrast in number.
Figure 2 Distribution of percentage of synergistic cases under various parameter sets for all combinations studied. Consistently synergistic and antagonistic combinations are marked, showing their stark contrast in number.CC BY · PubMed Central
Figure 3 Distribution of CIt values for several combinations. The combinations are shown in insets and the targets inhibited marked by crosses. These combinations are all highly consistent in showing either synergy or antagonism under 90% of parameterizing conditions.
Figure 3 Distribution of CIt values for several combinations. The combinations are shown in insets and the targets inhibited marked by crosses. These combinations are all highly consistent in showing either synergy or antagonism under 90% of parameterizing conditions.CC BY · PubMed Central
Figure 4 List of basic motifs that could result in drug synergy. Red dotted arrows indicate inhibitory actions, while blue arrows indicate activations. The targeting links of the drug combinations are marked by crosses in each network.
Figure 4 List of basic motifs that could result in drug synergy. Red dotted arrows indicate inhibitory actions, while blue arrows indicate activations. The targeting links of the drug combinations are marked by crosses in each network.CC BY · PubMed Central
Figure 5 Comparison of distributions of average CIt's for parallel and serial combinations. Definitions of parallel and serial combinations are presented in the main text.
Figure 5 Comparison of distributions of average CIt's for parallel and serial combinations. Definitions of parallel and serial combinations are presented in the main text.CC BY · PubMed Central
Figure 6 List of antagonistic combinations found in our study.
Figure 6 List of antagonistic combinations found in our study.CC BY · PubMed Central
Figure 7 Basic structure of the growth factor signaling pathway, showing examples of serial and parallel combinations.
Figure 7 Basic structure of the growth factor signaling pathway, showing examples of serial and parallel combinations.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

Sorted by citations

Items 101–139 of 139

Related

See all

Metadata

Authors
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L.
Affiliations
  • Peking University (CN)
  • Harvard University (US)
Corresponding author
Lai, Luhua
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2014-04-08
Volume
9
Issue
4
Pages
e93960
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0093960
PMC
PMC3979733
OpenAlex
W2015789827
Cited by
139
References
36
Citations by year
2026: 2 · 2025: 12 · 2024: 12 · 2023: 22 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 15 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 7 · 2014: 2
FWCI
3.96
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • National Natural Science Foundation of China (91313302, 90913021, 81273436, 2012AA020301, 2012AA020308)
  • National Institute on Alcohol Abuse and Alcoholism (R01AA020308)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
combination therapy, drug synergy, drug antagonism, network topology, drug-target network, three-node network, positive feedback loop, network motifs
MeSH terms
Drug Combinations, Drug Interactions, Drug Synergism, Models, Theoretical, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review